Lower risk for diabetes seen for those with normal fasting glucose, not impaired fasting glucose
WEDNESDAY, Jan. 16, 2019 (HealthDay News) — For individuals with normal fasting glucose but not those with impaired fasting glucose (IFG), a higher number of ideal cardiovascular health (CVH) components correlates with a lower risk for diabetes, according to a study published online Jan. 15 in Diabetologia.
Joshua J. Joseph, M.D., from The Ohio State University Wexner Medical Center in Columbus, and colleagues conducted a secondary data analysis in the Reasons for Geographic and Racial Differences in Stroke study. Incident diabetes was assessed among 7,758 participants without diabetes in 2003 to 2007; participants were followed for 9.5 years. Participants were characterized based on the number of ideal CVH components (zero to one, two to three, and four or more).
The researchers identified 891 incident diabetes cases. For participants with four or more versus zero to one ideal CVH components, the risk was reduced significantly among those with normal fasting glucose (risk ratio, 0.20; 95 percent confidence interval, 0.10 to 0.37) and reduced nonsignificantly with baseline IFG (risk ratio, 0.87; 95 percent confidence interval, 0.58 to 1.30). Compared with African-Americans, white participants had a stronger magnitude for the association between ideal CVH components and lower diabetes risk (P for interaction = 0.0338).
“The lower magnitude of risk reduction with ideal CVH among those with IFG warrants further investigation and suggests this group requires higher intensity interventions to lower long-term diabetes risk,” the authors write.
Two authors disclosed financial ties to Amgen.
Abstract/Full Text (subscription or payment may be required)
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis